...the drugs being tested in these trials are not the basis of my guarded optimism. Rather, I’m encouraged because leading universities are opening up to the idea that anti-aging therapies can solve our healthcare and budget crises.
Superior therapies are, in fact, forthcoming. Here are my updated predictions:
At least one geroprotective drug (possibly two or even three) that vastly outperforms rapamycin will emerge in the next two years. Because it will treat several pediatric orphan indications, it will breeze through the regulatory process.
The first age-reversing drug to market will be approved for a single indication but will prevent or cure a plethora of age-related diseases. Finally, all the diseases that plague humans in their old age will be recognized as symptoms of a single root disease with specific molecular mechanisms that can be reversed.
Within a few more years, complete rejuvenation of damaged organs or limbs will enter clinical trials either in the US, Israel, or Japan. This biotechnology, like the geroprotector I’ve already mentioned, will exploit our genomes’ latent embryonic pathways to restore youthful adult health.
No comments:
Post a Comment